Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LXEO
STRONG SELLLexeo Therapeutics, Inc. · Healthcare · United States · $366M · Avg Vol: $5M/d
COMPANY DESCRIPTION
Lexeo Therapeutics, Inc. is a clinical-stage gene therapy company focused on developing therapies for genetically defined cardiovascular, CNS, and other rare diseases. It utilizes a proprietary AAV gene therapy platform to target specific genetic defects, aiming to deliver one-time corrective treatments. The company is a specialized biotech company innovating in the gene therapy space, focusing on precision medicine for serious and often debilitating conditions.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.7M | 0.7M | 0 | 0 | 0 | -60.5% | — | — | 6.1M | 56.4% |
| EPS | -2.01 | -0.75 | -4.21 | -1.30 | -1.86 | — | -1.09 | -1.14 | -1.34 | — |
| Shares | 25.2M | 78.5M | 78.5M | 78.5M | 73.0M | +190.0% | 78.5M | — | — | — |
| Debt | 0 | 13.5M | 11.6M | 9.9M | 7.9M | -16.4% | 7.4M | — | — | — |
| Equity | -55.6M | -113.0M | 113.5M | 116.8M | 246.7M | 47.4% | — | — | — | — |
| Op CF | -44.2M | -54.6M | -59.5M | -81.2M | -98.6M | — | -98.0M | — | — | — |
| Inv CF | -0.2M | -0.9M | -0.2M | -94.1M | -90.3M | — | — | — | — | — |
| Fin CF | 150.9M | 0.2M | 103.8M | 88.8M | 216.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LXEO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LXEO | Lexeo Therapeutics, Inc.(you) | $366M | 13 | STRONG SELL |
| DMAC | DiaMedica Therapeutics Inc. | $363M | 12 | STRONG SELL |
| INDP | Indaptus Therapeutics, Inc. | $348M | 12 | STRONG SELL |
| RCKT | Rocket Pharmaceuticals, Inc. | $348M | 16 | STRONG SELL |
| CABA | Cabaletta Bio, Inc. | $439M | 15 | STRONG SELL |
| UPB | Upstream Bio, Inc. | $349M | 8 | STRONG SELL |
| CMPX | Compass Therapeutics, Inc. | $373M | 7 | STRONG SELL |
| EIKN | Eikon Therapeutics, Inc. | $482M | 12 | STRONG SELL |
| DNA | Ginkgo Bioworks Holdings, Inc. | $481M | 15 | STRONG SELL |
| STRO | Sutro Biopharma, Inc. | $379M | 20 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%